Show results for
Refine by
Immunotherapeutics Equipment Supplied In France
19 equipment items found
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
OSE’s R&D team and its academic partners have characterized the myeloid checkpoint CLEC-1 (a C-type lectin receptor) as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel “Don’t Eat Me” signal. CLEC-1 antagonist monoclonal antibodies have been identified as an innovative cancer immunotherapy that releases the ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A humanized monoclonal antibody, is an antagonist of the alpha chain of the interleukine-7 receptor, CD127, present on T effector cells, thus down regulating the immune activity. Interleukin-7 (IL-7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory T-cell down regulation. CD28 receptor is expressed on the surface of the majority of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Most anti-inflammatory agents act using a mechanism that blocks pro-inflammation pathways. In contrast, OSE Immunotherapeutics is developing OSE-230 as a first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to complete the inflammation program and restore tissue ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to tumor activity and responsiveness to ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor Origin (TO), Homologous Recombination Deficiency (HRD), DPYD ...
Manufactured by:Enterome based inParis, FRANCE
EO2401 is an innovative, off-the-shelf immunotherapy discovered by ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:Brenus Pharma based inIssoire, FRANCE
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer ...
Manufactured by:Inovarion based inParis, FRANCE
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The mechanisms of oncogenesis, resistance to treatments and the identification of diagnostic biomarkers are major areas of research. Our teams can intervene on a ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:SEQENS Group based inÉcully, FRANCE
Our Drug Delivery Solutions Business Unit coordinates our Custom Lipids activity. Seqens strongly believes in the potential of new cutting-edge technologies. In the pharmaceutical industry, lipids and polymers are core excipients in the development of drug delivery systems. Lipids and polymers can be used in most dosage forms as support vehicles, solubilizers, permeation enhancers, stabilizers, ...
Manufactured by:Angany Inc. based inSt-Jean, QUEBEC (CANADA)
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The fight against allergy is at the heart of ANGANY’s mission. And it is to overcome the specific challenges of allergy that ANGANY has developed a ...
Manufactured by:Angany Inc. based inSt-Jean, QUEBEC (CANADA)
We aim to provide safe, dependable and lasting relief from allergy. We have developed a unique therapeutic approach based on a proprietary allergy vaccine technology to address the specific challenge of allergy (eBioparticle-Potentiated ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...